AEterna Zentaris Inc. (NASDAQ:AEZS) Price Target Raised to $4.00
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) had its price objective increased by stock analysts at Maxim Group from $2.00 to $4.00 in a report issued on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price would suggest a potential upside of 292.16% from the company’s current price.
Other equities research analysts also recently issued reports about the company. Zacks Investment Research raised AEterna Zentaris from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. HC Wainwright cut their price target on AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating on the stock in a research report on Wednesday, May 10th.
Shares of AEterna Zentaris (NASDAQ:AEZS) traded up 160.78% during mid-day trading on Wednesday, hitting $2.66. The company had a trading volume of 42,646,659 shares. AEterna Zentaris has a 1-year low of $0.78 and a 1-year high of $5.59. The company’s market capitalization is $38.13 million. The company has a 50-day moving average price of $1.02 and a 200-day moving average price of $2.16.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. AEterna Zentaris had a negative return on equity of 425.52% and a negative net margin of 2,732.69%. The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.85 million. During the same period in the prior year, the firm earned ($0.37) EPS. The firm’s revenue was up 8.3% on a year-over-year basis. On average, equities analysts anticipate that AEterna Zentaris will post ($1.39) EPS for the current year.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.